Log in
NYSE:SYK

Stryker Competitors

$205.39
+0.44 (+0.21 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$202.27
Now: $205.39
$208.52
50-Day Range
$198.96
MA: $212.59
$225.63
52-Week Range
$124.54
Now: $205.39
$227.39
Volume1.00 million shs
Average Volume1.71 million shs
Market Capitalization$76.99 billion
P/E Ratio48.79
Dividend Yield1.12%
Beta0.78

Competitors

Stryker (NYSE:SYK) Vs. ABT, MDT, ISRG, BDX, BSX, and EW

Should you be buying SYK stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Stryker, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Abbott Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Abbott Laboratories and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.30%8.32%
Stryker11.38%20.53%8.89%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Stryker291612.57

Abbott Laboratories currently has a consensus price target of $115.1250, suggesting a potential upside of 9.64%. Stryker has a consensus price target of $220.68, suggesting a potential upside of 7.44%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe Abbott Laboratories is more favorable than Stryker.

Dividends

Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Abbott Laboratories and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion5.83$3.69 billion$3.2432.41
Stryker$14.88 billion5.17$2.08 billion$8.2624.87

Abbott Laboratories has higher revenue and earnings than Stryker. Stryker is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

73.1% of Abbott Laboratories shares are held by institutional investors. Comparatively, 71.0% of Stryker shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medtronic (NYSE:MDT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Medtronic has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Stryker11.38%20.53%8.89%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Medtronic and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132212.85
Stryker291612.57

Medtronic currently has a consensus price target of $117.8571, suggesting a potential upside of 16.26%. Stryker has a consensus price target of $220.68, suggesting a potential upside of 7.44%. Given Medtronic's stronger consensus rating and higher possible upside, research analysts plainly believe Medtronic is more favorable than Stryker.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.3%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Medtronic and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion4.71$4.79 billion$4.5922.08
Stryker$14.88 billion5.17$2.08 billion$8.2624.87

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 71.0% of Stryker shares are held by institutional investors. 0.5% of Medtronic shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Stryker beats Medtronic on 9 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Stryker and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Intuitive Surgical24.45%12.08%10.44%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Stryker and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
Intuitive Surgical371202.41

Stryker presently has a consensus target price of $220.68, indicating a potential upside of 7.44%. Intuitive Surgical has a consensus target price of $718.2778, indicating a potential upside of 4.66%. Given Stryker's stronger consensus rating and higher possible upside, equities research analysts plainly believe Stryker is more favorable than Intuitive Surgical.

Risk and Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Stryker and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.17$2.08 billion$8.2624.87
Intuitive Surgical$4.48 billion18.01$1.38 billion$9.9568.97

Stryker has higher revenue and earnings than Intuitive Surgical. Stryker is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Stryker and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Becton, Dickinson and5.30%14.19%5.86%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Stryker and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
Becton, Dickinson and07712.60

Stryker presently has a consensus target price of $220.68, indicating a potential upside of 7.44%. Becton, Dickinson and has a consensus target price of $280.8571, indicating a potential upside of 20.81%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Stryker.

Volatility & Risk

Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Insider and Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 84.2% of Becton, Dickinson and shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.1%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and lower payout ratio.

Valuation and Earnings

This table compares Stryker and Becton, Dickinson and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.17$2.08 billion$8.2624.87
Becton, Dickinson and$17.29 billion3.90$1.23 billion$11.6819.90

Stryker has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Stryker on 9 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Stryker and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Boston Scientific39.18%12.86%5.76%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Stryker and Boston Scientific, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
Boston Scientific031833.00

Stryker presently has a consensus target price of $220.68, indicating a potential upside of 7.44%. Boston Scientific has a consensus target price of $44.3478, indicating a potential upside of 32.38%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Risk and Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 90.2% of Boston Scientific shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Stryker and Boston Scientific's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.17$2.08 billion$8.2624.87
Boston Scientific$10.74 billion4.46$4.70 billion$1.5821.20

Boston Scientific has lower revenue, but higher earnings than Stryker. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Stryker on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Stryker and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Edwards Lifesciences17.21%29.11%18.32%

Valuation & Earnings

This table compares Stryker and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.17$2.08 billion$8.2624.87
Edwards Lifesciences$4.35 billion10.45$1.05 billion$1.8639.20

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Stryker and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291612.57
Edwards Lifesciences251302.55

Stryker presently has a consensus target price of $220.68, indicating a potential upside of 7.44%. Edwards Lifesciences has a consensus target price of $87.1481, indicating a potential upside of 19.53%. Given Edwards Lifesciences' higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Stryker.

Risk and Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats Stryker on 8 of the 15 factors compared between the two stocks.


Stryker Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
1.8$105.00+1.4%$185.91 billion$31.90 billion55.56Analyst Downgrade
Insider Selling
Medtronic logo
MDT
Medtronic
2.3$101.37+1.2%$136.26 billion$28.91 billion31.00
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.5$686.28+0.2%$80.68 billion$4.48 billion78.16Insider Selling
Becton, Dickinson and logo
BDX
Becton, Dickinson and
1.7$232.47+1.5%$67.39 billion$17.29 billion83.62Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.1$33.50+1.7%$47.93 billion$10.74 billion11.88Earnings Announcement
Analyst Downgrade
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$72.91+0.5%$45.44 billion$4.35 billion62.67Analyst Report
Insider Selling
Analyst Revision
Baxter International logo
BAX
Baxter International
2.0$78.08+0.1%$39.53 billion$11.36 billion23.59Earnings Announcement
Increase in Short Interest
Heavy News Reporting
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.2$441.80+4.3%$37.58 billion$2.41 billion83.52Earnings Announcement
Heavy News Reporting
DexCom logo
DXCM
DexCom
1.7$335.29+4.1%$32.10 billion$1.48 billion153.10Earnings Announcement
Analyst Report
Insider Selling
Unusual Options Activity
Analyst Revision
ResMed logo
RMD
ResMed
1.6$179.51+0.6%$26.01 billion$2.96 billion42.04Earnings Announcement
Analyst Upgrade
Hologic logo
HOLX
Hologic
1.5$70.50+1.1%$18.26 billion$3.37 billion28.54Upcoming Earnings
Analyst Upgrade
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$172.28+0.1%$15.67 billion$3.23 billion56.12Earnings Announcement
Analyst Downgrade
Increase in Short Interest
Teleflex logo
TFX
Teleflex
1.7$326.65+2.6%$15.19 billion$2.60 billion32.15Earnings Announcement
Dividend Announcement
High Trading Volume
Steris logo
STE
Steris
1.9$177.33+0.7%$15.08 billion$3.03 billion36.87Upcoming Earnings
Insulet logo
PODD
Insulet
1.4$228.72+0.1%$15.02 billion$738.20 million816.89Upcoming Earnings
Analyst Downgrade
Masimo logo
MASI
Masimo
1.4$225.68+3.5%$12.40 billion$937.84 million58.47Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
ABIOMED logo
ABMD
ABIOMED
1.2$254.61+11.2%$11.47 billion$840.88 million73.37Earnings Announcement
Heavy News Reporting
Hill-Rom logo
HRC
Hill-Rom
1.7$92.83+1.7%$6.18 billion$2.91 billion29.95Upcoming Earnings
Insider Selling
Decrease in Short Interest
Globus Medical logo
GMED
Globus Medical
1.8$52.47+5.4%$5.13 billion$785.37 million61.01Earnings Announcement
Analyst Report
Increase in Short Interest
Heavy News Reporting
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$30.60+0.0%$3.97 billion$920.90 million-28.87
Integra LifeSciences logo
IART
Integra LifeSciences
1.7$43.31+1.3%$3.65 billion$1.52 billion-1,443.67Earnings Announcement
Analyst Report
Decrease in Short Interest
Heavy News Reporting
NuVasive logo
NUVA
NuVasive
1.6$49.27+3.2%$2.53 billion$1.17 billion-410.58Earnings Announcement
Heavy News Reporting
CONMED logo
CNMD
CONMED
1.4$83.12+4.4%$2.37 billion$955.10 million87.49Earnings Announcement
Integer logo
ITGR
Integer
1.8$61.03+0.1%$2.00 billion$1.26 billion27.74Earnings Announcement
AtriCure logo
ATRC
AtriCure
1.6$35.50+2.8%$1.60 billion$230.81 million-27.52Upcoming Earnings
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$36.16+0.8%$1.45 billion$236.54 million-46.36Upcoming Earnings
Analyst Upgrade
Decrease in Short Interest
Alphatec logo
ATEC
Alphatec
1.6$8.97+5.7%$696.95 million$113.43 million-8.01Upcoming Earnings
Increase in Short Interest
CryoLife logo
CRY
CryoLife
2.2$17.37+1.3%$657.59 million$276.22 million-57.90Upcoming Earnings
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$31.66+0.9%$611.92 million$459.95 million-26.83Upcoming Earnings
Heavy News Reporting
Surmodics logo
SRDX
Surmodics
1.4$38.76+1.7%$527.37 million$100.08 million69.21Upcoming Earnings
Analyst Downgrade
AngioDynamics logo
ANGO
AngioDynamics
2.3$10.66+0.6%$404.58 million$264.16 million-2.41Heavy News Reporting
Accuray logo
ARAY
Accuray
1.5$2.79+1.8%$254.44 million$382.93 million93.00Analyst Downgrade
Increase in Short Interest
Invacare logo
IVC
Invacare
1.4$7.19+2.5%$247.47 million$927.96 million-5.71Earnings Announcement
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.87+3.4%$61.15 million$61.30 million-1.93
This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.